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rted in vivo platelet activation during 
thrombolysi6 wi streptokinase (SK) and TPA is due to a 
direct effect of the thrombolytic agents on platelets or 
t0 increased platelet-vessel wall interaction is 
We therefore assessed the direct effects of SKI 
urokinase (UK) on platelets in vitro. With both 
and collagen (1 pg/mlJ as aggregating 
agents* SK at 100 units/ml led to a significant (pe 
0.05) mean reduction in the rate of platelet aggregation 
(PA). With collagen and* in most instances with ADP, 
this reduction in the rate of PA was associated with a 
decreased extent of PA. In 5 out of 30 cases, however8 
with ADP as aggregating agent, a conversion from rever- 
sible to irreversible PA occurred with SK. Thus, PA 
seemed to be stimulated SK in these cases. TPA uni- 
formAy inhibited PA at 1 pg/ml with ADP and at 
/ml with collagen as aggregating agent, uI< inhibited 
at 300 units/ml with both aggregating agents. 
Platelet inhibition by the thrombolytlcs still occurred 
when the platelets were suspended in saline and, thus 0 
does not seem to be dependent on plasmatic factors. 
Platelet synthesis of both thromboxane after stimulation 
with collagen, and C-AMP after prostsglandin El was 
markedly reduced by either agent. 
Thus, SK, TPA and UK inhibited platelets in vitro@ 
although with SK, in a minority of casesI platelet 
stimulation was observed. In vivo platelet activation 
during thrombolysis should therefore not be due to a 
direct effect of the thrombolytic drugs on platelets. 
congestion. 
